BR112019010646A2 - métodos de tratamento de condições inflamatórias - Google Patents

métodos de tratamento de condições inflamatórias

Info

Publication number
BR112019010646A2
BR112019010646A2 BR112019010646A BR112019010646A BR112019010646A2 BR 112019010646 A2 BR112019010646 A2 BR 112019010646A2 BR 112019010646 A BR112019010646 A BR 112019010646A BR 112019010646 A BR112019010646 A BR 112019010646A BR 112019010646 A2 BR112019010646 A2 BR 112019010646A2
Authority
BR
Brazil
Prior art keywords
methods
present
treating inflammatory
inflammatory conditions
antagonist
Prior art date
Application number
BR112019010646A
Other languages
English (en)
Inventor
J Murphy Andrew
D Yancopoulos George
M Orengo Jamie
ALLINNE Jeanne
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112019010646A2 publication Critical patent/BR112019010646A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)

Abstract

a presente invenção provê métodos para o tratamento de doenças inflamatórias ou condições associadas ou resultantes, em parte, de níveis elevados de il-33 e il-4, em particular distúrbios pulmonares inflamatórios. os métodos da presente invenção compreendem a administração a um indivíduo em necessidade do mesmo de uma ou mais doses terapeuticamente eficazes de um antagonista de il-33, isoladamente ou em combinação com uma ou mais doses terapeuticamente eficazes de um antagonista de il-4r. em certas modalidades, os métodos da presente invenção incluem a utilização dos antagonistas para tratar qualquer doença ou condição inflamatória mediada, em parte, por sinalização mediada por il-33 e sinalização mediada por il-4 aumentadas.
BR112019010646A 2016-12-01 2017-11-30 métodos de tratamento de condições inflamatórias BR112019010646A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662428634P 2016-12-01 2016-12-01
US201762473738P 2017-03-20 2017-03-20
US201762567318P 2017-10-03 2017-10-03
PCT/US2017/064041 WO2018102597A1 (en) 2016-12-01 2017-11-30 Methods of treating inflammatory conditions

Publications (1)

Publication Number Publication Date
BR112019010646A2 true BR112019010646A2 (pt) 2019-10-01

Family

ID=60788696

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019010646A BR112019010646A2 (pt) 2016-12-01 2017-11-30 métodos de tratamento de condições inflamatórias

Country Status (19)

Country Link
US (3) US10815305B2 (pt)
EP (1) EP3548513A1 (pt)
JP (3) JP7132220B2 (pt)
KR (2) KR20240033187A (pt)
CN (2) CN118662629A (pt)
AU (1) AU2017367691B2 (pt)
BR (1) BR112019010646A2 (pt)
CA (1) CA3044851A1 (pt)
CL (1) CL2019001475A1 (pt)
CO (1) CO2019005236A2 (pt)
CR (1) CR20190311A (pt)
IL (1) IL266770B2 (pt)
MA (1) MA46954A (pt)
MX (2) MX2019006177A (pt)
PH (1) PH12019501120A1 (pt)
TN (1) TN2019000172A1 (pt)
TW (1) TWI784988B (pt)
UA (1) UA127965C2 (pt)
WO (1) WO2018102597A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110624107A (zh) 2012-08-21 2019-12-31 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗或预防哮喘的方法
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
EP3610041A1 (en) 2017-04-13 2020-02-19 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
CA3066918A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
WO2019198703A1 (ja) 2018-04-10 2019-10-17 日立化成株式会社 エポキシ樹脂、エポキシ樹脂組成物、エポキシ樹脂硬化物及び複合材料
IL277890B2 (en) 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantification of IL-33
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
WO2020150633A1 (en) * 2019-01-18 2020-07-23 Orthobio Therapeutics, Inc. Gene editing to improve joint function
TW202102260A (zh) 2019-03-21 2021-01-16 美商再生元醫藥公司 含有抗ｉｌ－３３抗體之穩定調配物
TW202106334A (zh) * 2019-05-01 2021-02-16 法商賽諾菲生物技術公司 藉由投予ｉｌ－３３拮抗劑治療或預防哮喘之方法
AU2020398168A1 (en) * 2019-12-06 2022-07-28 Regeneron Pharmaceuticals, Inc. Methods for treating COPD by administering an IL-33 antagonist
MX2022007958A (es) * 2019-12-23 2022-10-07 Sanofi Biotechnology Metodos para tratar o prevenir el asma alergica mediante la administracion de un antagonista de il-33 y/o un antagonista de il-4r.
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
EP4132972A1 (en) 2020-04-06 2023-02-15 MedImmune Limited Treating acute respiratory distress syndrome with il-33 axis binding antagonists
CN113527485A (zh) * 2020-04-17 2021-10-22 上海麦济生物技术有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
CN113549151A (zh) * 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
CN111714619B (zh) * 2020-07-15 2023-03-14 上海市浦东新区人民医院 成纤维生长因子6在制备缓解非酒精性脂肪性肝炎肝损伤的药物中的应用
CN117858898A (zh) * 2021-08-27 2024-04-09 免疫医疗有限公司 用抗白介素-33抗体治疗慢性阻塞性肺病
MX2024005769A (es) * 2021-11-11 2024-05-24 Regeneron Pharma Tratamiento de la enfermedad pulmonar basado en la estratificacion de puntuacion de riesgo poligenico para la interleucina 33 (il-33).

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8808015D0 (en) 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
JPH06510750A (ja) 1991-05-03 1994-12-01 セラジェン　インク 炎症性関節炎治療を目的としてインタ−ロイキン受容体を標的にした分子
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5714146A (en) 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ZA946875B (en) 1993-09-07 1995-07-06 Smithkline Beecham Corp Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US5576191A (en) 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
JP2003524602A (ja) 1998-09-18 2003-08-19 ダイナバックス テクノロジーズ コーポレイション ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
CN1507353A (zh) 2001-05-11 2004-06-23 ��˹��ŵ�� 用于治疗IgE相关性疾病的组合物
DE60233519D1 (de) 2001-05-23 2009-10-08 Duotol Ab Unterdrückung von allergischen reaktionen durch transkutane verabreichung von allergenen zusammen mit oder fusioniert mit toxinuntereinheiten oder deren fragmenten
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
WO2004056868A2 (en) 2002-12-19 2004-07-08 Endocube Sas Nf-hev compositions and methods of use
CN1829806A (zh) 2003-02-01 2006-09-06 唐纳士公司 产生高亲和力抗体的方法
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
GEP20104991B (en) 2003-11-07 2010-05-25 Immunex Corp Antibodies that bind interleukin-4 receptor
WO2005063817A2 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JP2008504806A (ja) 2004-02-27 2008-02-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ−４／ｉｌ−１３特異的ポリペプチドおよびその治療上の使用
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
WO2007140205A2 (en) 2006-05-24 2007-12-06 Biogen Idec Ma Inc. Methods of treating fibrosis
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
DK2769992T3 (da) 2006-10-02 2021-03-22 Regeneron Pharma Humane antistoffer med høj affinitet for human IL-4-receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2008132709A1 (en) 2007-04-26 2008-11-06 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Products for altering il-33 activity and methods therefor
JP2010527936A (ja) 2007-05-18 2010-08-19 メディミューン，エルエルシー 炎症性疾患におけるｉｌ−３３
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20100310575A1 (en) 2007-10-26 2010-12-09 Max-Planck-Gesellschaft Zur Forderung Der Wissensc Inhibitors of Caspase I-Dependent Cytokines in the Treatment of Neurodegenerative Disorders
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
AU2009322556A1 (en) 2008-12-01 2011-07-21 Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
JP5879265B2 (ja) 2009-09-07 2016-03-08 デベヴェ・テクノロジーズ 好酸球性食道炎を処置する方法
ES2655079T3 (es) 2009-09-10 2018-02-16 Merck Sharp & Dohme Corp. Uso de antagonistas de IL-33 para tratar enfermedades fibróticas
WO2011163614A2 (en) 2010-06-24 2011-12-29 Meritage Pharma, Inc. Methods of treatment for esophageal inflammation
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
EP2661631A4 (en) 2011-01-06 2014-05-21 Childrens Hosp Medical Center EXPRESSION PROFILES FOR OSSOPHAGEAL CYTOKINE IN EOSINOPHILIAN ESOPHAGITIS
CA2824500C (en) 2011-02-23 2020-02-25 Georg Fertig Antibodies against human il33r and uses thereof
WO2012177945A2 (en) 2011-06-21 2012-12-27 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
CN103974706A (zh) 2011-10-06 2014-08-06 N·V·努特里奇亚 嗜酸细胞性食管炎的治疗
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
RS57520B1 (sr) 2012-09-07 2018-10-31 Regeneron Pharma Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r
WO2014059178A1 (en) 2012-10-10 2014-04-17 Rhode Island Hospital Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
CA2904377C (en) 2013-03-15 2021-07-13 Regeneron Pharmaceuticals, Inc. Il-33 antagonists and uses thereof
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20230066127A (ko) * 2013-06-21 2023-05-12 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
FI3088517T3 (fi) 2013-12-26 2023-11-30 Mitsubishi Tanabe Pharma Corp Ihmisen Anti-IL-33 neutraloiva monoklonaalinen vasta-aine
EP3092253B1 (en) 2014-01-10 2021-03-17 AnaptysBio, Inc. Antibodies directed against interleukin-33 (il-33)
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by adding an IL-4R antagonist
AU2015222951B2 (en) 2014-02-28 2020-06-11 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an IL-4R antagonist
NO2785538T3 (pt) * 2014-05-07 2018-08-04
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック， インコーポレイテッド Ｉｌ－３３媒介性障害のための治療及び診断方法
WO2016156440A1 (en) 2015-03-31 2016-10-06 Medimmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法

Also Published As

Publication number Publication date
CN110167963A (zh) 2019-08-23
CA3044851A1 (en) 2018-06-07
WO2018102597A1 (en) 2018-06-07
MX2023008368A (es) 2023-07-26
US20240209102A1 (en) 2024-06-27
MA46954A (fr) 2019-10-09
CN110167963B (zh) 2024-06-14
JP7351989B2 (ja) 2023-09-27
TWI784988B (zh) 2022-12-01
JP2020513404A (ja) 2020-05-14
CN118662629A (zh) 2024-09-20
KR20190086471A (ko) 2019-07-22
KR20240033187A (ko) 2024-03-12
AU2017367691B2 (en) 2024-09-26
KR102645242B1 (ko) 2024-03-13
CO2019005236A2 (es) 2019-05-31
US10815305B2 (en) 2020-10-27
JP7132220B2 (ja) 2022-09-06
PH12019501120A1 (en) 2019-08-19
US20180155436A1 (en) 2018-06-07
CL2019001475A1 (es) 2019-08-16
US20210079105A1 (en) 2021-03-18
TN2019000172A1 (en) 2020-10-05
IL266770B2 (en) 2023-10-01
EP3548513A1 (en) 2019-10-09
US11866503B2 (en) 2024-01-09
UA127965C2 (uk) 2024-02-28
IL266770A (en) 2019-07-31
IL266770B1 (en) 2023-06-01
TW201827079A (zh) 2018-08-01
MX2019006177A (es) 2019-08-29
TW202332696A (zh) 2023-08-16
JP2023175785A (ja) 2023-12-12
CR20190311A (es) 2019-08-20
JP2022174089A (ja) 2022-11-22
AU2017367691A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
BR112019010646A2 (pt) métodos de tratamento de condições inflamatórias
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
CL2021000343A1 (es) Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128)
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
EA202190661A1 (ru) Агонисты фарнезоидного х-рецептора для лечения заболевания
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
BR112017025045A2 (pt) plx-8394 ou plx-7904 para uso no tratamento de doenças relacionadas a braf-v600
MX2019010994A (es) Metodos para tratar enfermedades y trastornos mediados por el complemento.
BR112017008093A2 (pt) processos para tratamento de doenças oculares
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
BR112015026122A2 (pt) métodos para usar interleucina-10 para tratar doenças e desordens
BR112015030385A2 (pt) inibidores de pi3 delta e gama quinase seletivos duplos
BR112016025764A2 (pt) vacina de peptídeo compreendendo peptídeo ras mutante e agente quimioterapêutico
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
BR112019005985A2 (pt) composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112021018262A2 (pt) Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina
BR112019004684A2 (pt) combinação de agonistas de fxr
WO2016030334A3 (en) Methods, agents and compositions for treatment of inflammatory conditions
BR112019002355A2 (pt) composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
BR112018000568A2 (pt) antagonistas do receptor 5-ht6 para uso no tratamento da doença de alzheimer com apatia como comorbidade
BR112014028446A2 (pt) composto isolado, composição farmacêutica, método de tratamento ou prevenção de pelo menos um de doenças, distúrbios ou condições seguintes, e, método de tratamento ou prevenção de um distúrbio de ritmo circadiano ou distúrbio com um componente circadiano em um indivíduo
BR112018067967A2 (pt) tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante
EP3639854A4 (en) MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]